Value, Affordability, and Decision Making
Efficient allocation of healthcare budgets requires a clear understanding of whether interventions deliver good value for money. Resource-allocation decisions should therefore follow structured, transparent, and evidence-based processes that consider value, equity, and affordability.
OHE advances innovative methodologies and drives international, policy-focused research to address these core dimensions . We provide evidence in support of robust, systematic, and comprehensive value assessments within healthcare systems, including Health Technology Assessment (HTA), and across other sectors.
Overall purpose of this research theme
To support systematic, fair, and evidence-based decision-making processes for resource allocation in healthcare.
Policy objectives
- Advance the development of novel value frameworks.
- Inform HTA methods and processes.
- Guide the purpose and role of HTA.
- Strengthen knowledge transfer and guidance for decision-makers.
Around the World in HTAs
Around the World in HTAs: Spain – Closer than ever, but not quite yet
Spain has introduced its first national legal framework for health technology assessment (HTA) through Royal Decree 415/2026. It is a significant step forward, but the system is still being built.
Read more
Around the world in HTAs: Abu Dhabi – Advancing HTA and value-based healthcare in the UAE
Abu Dhabi is taking important steps to strengthen the use of HTA in healthcare decision-making, with the publication of its HTA guidelines in 2025 marking an important milestone.
Read more
Around the World in HTAs: Japan – An algorithmic approach to containing costs
Japan’s health technology assessment (HTA) system uses algorithmic drug pricing and cost-effectiveness analysis to manage rising healthcare costs while maintaining universal access and innovation.
Read more
Around The World in HTAs: France – Three Core HTA Values
In the latest edition of our Insights series, Around the World in HTAs, we explore the HTA system in France. A special thanks to Salah Ghabri for his valuable support to write this note.
Read moreOur latest content on this theme
What the first EU JCA reveals about assessing precision oncology
We explore how the first JCA provides insights into the longstanding methodological challenge of evidence generation and comparative assessment for precision medicine.
Around the world in HTAs: Abu Dhabi – Advancing HTA and value-based healthcare in the UAE
Abu Dhabi is taking important steps to strengthen the use of HTA in healthcare decision-making, with the publication of its HTA guidelines in 2025 marking an important milestone.
The impact of inflation on incremental costs in HTA
Inflation reshapes the economic landscape in which new treatments are evaluated. Yet cost-effectiveness thresholds tend to remain fixed over time. This report examines how inflation in…
One Europe, one assessment? Unpacking the European Joint Clinical Assessment
As the first EU Joint Clinical Assessment reports approach, national HTA systems across Europe are already adapting to a new era of coordinated clinical evaluation.